Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » New Therapy for Rare Lymphoma
Clinical Breakthroughs

New Therapy for Rare Lymphoma

By Anna WilliamsAug 29, 2018
Share
Facebook Twitter Email
Barbara Pro, MD, professor of Medicine in the Division of Hematology and Oncology and a member of the Lurie Cancer Center, was a co-author of the study published in The Lancet Oncology.

A drug called mogamulizumab significantly improved progression-free survival for patients with cutaneous T-cell lymphoma, according to the results of a clinical trial published in The Lancet Oncology. The findings led to the FDA’s recent approval of the drug.

“For patients affected by this debilitating disease, we can now offer a novel and effective treatment option,” said co-author Barbara Pro, MD, professor of Medicine in the Division of Hematology and Oncology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Cutaneous T-cell lymphoma (CTCL) is a rare cancer of T-cell lymphocytes that primarily affects the skin. There is no cure, and the disease is difficult to treat, with few therapy options.

Mogamulizumab is a novel targeted therapy that binds to a protein called CCR4 that is expressed on the surface of malignant T-cells.

In a large multi-center phase III trial, 372 patients with the two most common subtypes of CTCL — Mycosis fungoides and Sézary syndrome — who had not responded to prior treatment were randomized to receive either mogamulizumab or vorinostat, a standard therapy.

The investigators found that treatment with mogamulizumab significantly prolonged progression-free survival, as compared to vorinostat. Mogamulizumab was also found to be superior in terms of quality of life and the proportion of patients who achieved an overall response.

Side effects of mogamulizumab were considered manageable, with the most common being infusion-related reactions, rash, diarrhea and fatigue.

Based on these findings, the FDA approved mogamulizumab for the treatment of adult patients with relapsed or refractory Mycosis fungoides and Sézary syndrome who had received at least one prior systemic therapy. It is the first FDA approval of a drug specifically for Sézary syndrome and also offers a new treatment option for patients with Mycosis fungoides.

The study was supported by Kyowa Kirin, which manufactures mogamulizumab.

Read more:

  • Lurie Cancer Center Earns Exceptional Rating from National Cancer Institute
  • Clinical Trials Show Promise in Leukemia
  • A New Weapon Against Cancer Metastasis
Cancer Research
Share. Facebook Twitter Email

Related Posts

Mapping Neural Activity Patterns and Odor Perception  

Sep 28, 2023

Small, Implantable Device Could Sense and Treat Cancer

Sep 26, 2023

Gene Linked to Glioblastoma Stem Cell Self-Renewal and Immunosuppression

Sep 26, 2023

Comments are closed.

Latest News

Mapping Neural Activity Patterns and Odor Perception  

Sep 28, 2023

Lloyd-Jones Announces He is Stepping Down as Chair of Preventive Medicine

Sep 27, 2023

Small, Implantable Device Could Sense and Treat Cancer

Sep 26, 2023

Gene Linked to Glioblastoma Stem Cell Self-Renewal and Immunosuppression

Sep 26, 2023

Northwestern Simulation’s In Situ Training Tests Cardiac Arrest Response Teams

Sep 25, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230914_NM461
20230914_NM644
20230914_NM345
20230914_NM444
20230914_NM464
20230914_NM520
20230914_NM673
20230914_NM641
20230914_NM612
20230914_NM608
20230914_NM602
20230914_NM597

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.